This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-08. Anything still debated is marked as such rather than presented as settled.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
According to the marketeer, the old name "McDonald's" will soon disappear from the lexicon of the Russian consumers, and, to not pronounce the long phrase, clients of the chain will make up their own. On 13 June, various messages appeared claiming that the logo of Vkusno i tochka is a lazy alteration of a Portuguese pet food brand "Matosmix". On 15 June, the director of a fast food chain known as "Food, full stop" (Russian: Еда и точка) in Primorsky Krai, Sergei Ponkratov, accused the new chain of plagiarism and decided to sue it, demanding a change of the name. He claims that the Vkusno i tochka brand clearly intersects with and deprives his trademark, which has been operating since 2018, of uniqueness and recognizability.
== Toxicokinetics == The kinetics of labeled derivatives of apamin were studied in vitro and in vivo in mice by Cheng-Raude et al. This shed some light on the kinetics of apamin itself. The key organ for excretion is likely to be the kidney, since enrichment of the labeled derivatives was found there. The peptide apamin is small enough to pass the glomerular barrier, facilitating renal excretion. The central nervous system, contrarily, was found to contain only very small amounts of apamin. This is unexpected, as this is the target organ for neurotoxicity caused by apamin. This low concentration thus appeared to be sufficient to cause the toxic effects. However, these results disagree with a study of Vincent et al. After injection of a supralethal dose of radioactive acetylated apamin in mice, enrichment was found in the spinal cord, which is part of the target organ. Some other organs, including kidney and brain, contained only small amounts of the apamin derivative.
In 1937, the administration of BST was shown to increase the milk yield in lactating cows by preventing mammary cell death in dairy cattle. Until the 1980s, use of the compound was very limited in agriculture as the sole source of the hormone was from bovine carcasses. During this time, the knowledge of the structure and function of the hormone increased. With the advent of biotechnology, one of the pioneering biotech companies, Genentech, in 1981 succeeded in cloning and patenting the gene for BST. Monsanto had been working along the same lines and struck a deal with Genentech in 1979 to license Genentech's patents and collaborate on development of a recombinant version of BST – a process on which Monsanto would invest $300 million. The two companies used genetic engineering to clone the BST gene into E. coli. The bacteria are grown in bioreactors, then broken up and separated from the rBST, which is purified to produce the injectable hormone. They published their first field trial results in 1981. Lilly, American Cyanamid, Upjohn, and Monsanto all submitted applications to market rBST to the FDA, and the FDA completed its review of the human safety component of these applications in 1986 and found food from rBST-treated cows to be safe; however, strong public concern led to calls for more studies, investigations, and public discussions, which included an unprecedented conference on the safety of rBST in 1990 organized by the National Institutes of Health at the request of Senator Patrick Leahy. FDA approved Monsanto's application in 1993.
Sources: en.wikipedia.org
(The total force applied to the longer dam will be greater, due to the greater total surface area for the pressure to act upon. But for a given 5-foot (1.5 m)-wide section of each dam, the 10 ft (3.0 m) deep water will apply one quarter the force of 20 ft (6.1 m) deep water). A person will feel the same pressure whether their head is dunked a metre beneath the surface of the water in a small pool or to the same depth in the middle of a large lake. If four interconnected vases contain different amounts of water but are all filled to equal depths, then a fish with its head dunked a few centimetres under the surface will be acted on by water pressure that is the same in any of the vases. If the fish swims a few centimetres deeper, the pressure on the fish will increase with depth and be the same no matter which vase the fish is in. If the fish swims to the bottom, the pressure will be greater, but it makes no difference which vase it is in. All vases are filled to equal depths, so the water pressure is the same at the bottom of each vase, regardless of its shape or volume. If water pressure at the bottom of a vase were greater than water pressure at the bottom of a neighboring vase, the greater pressure would force water sideways and then up the neighboring vase to a higher level until the pressures at the bottom were equalized. Pressure is depth dependent, not volume dependent, so there is a reason that water seeks its own level. Restating this as an energy equation, the energy per unit volume in an ideal, incompressible liquid is constant throughout its vessel.
Early examples of artistic expression, such as the Venus of Tan-Tan and the patterns found on elephant bones from Bilzingsleben in Thuringia, may have been produced by Acheulean tool users such as Homo erectus prior to the start of the Middle Paleolithic period. However, the earliest undisputed evidence of art during the Paleolithic comes from Middle Paleolithic/Middle Stone Age sites such as Blombos Cave–South Africa–in the form of bracelets, beads, rock art, and ochre used as body paint and perhaps in ritual. Undisputed evidence of art only becomes common in the Upper Paleolithic. Lower Paleolithic Acheulean tool users, according to Robert G. Bednarik, began to engage in symbolic behavior such as art around 850,000 BP. They decorated themselves with beads and collected exotic stones for aesthetic, rather than utilitarian qualities. According to him, traces of the pigment ochre from late Lower Paleolithic Acheulean archaeological sites suggests that Acheulean societies, like later Upper Paleolithic societies, collected and used ochre to create rock art. Nevertheless, it is also possible that the ochre traces found at Lower Paleolithic sites is naturally occurring. Upper Paleolithic humans produced works of art such as cave paintings, Venus figurines, animal carvings, and rock paintings. Upper Paleolithic art can be divided into two broad categories: figurative art such as cave paintings that clearly depicts animals (or more rarely humans); and nonfigurative, which consists of shapes and symbols.
Some segments of the 1960s hippie counterculture grew to dislike urban living and developed a preference for locally autonomous, sustainable, and decentralized technology, termed appropriate technology. This later influenced hacker culture and technopaganism.
Sources: en.wikipedia.org
It was first detected spectroscopically in late 1931 by Harold Urey, a chemist at Columbia University. Urey's collaborator, Ferdinand Brickwedde, distilled five liters of cryogenically produced liquid hydrogen to 1 mL of liquid, using the low-temperature physics laboratory that had recently been established at the National Bureau of Standards (now National Institute of Standards and Technology) in Washington, DC. The technique had previously been used to isolate heavy isotopes of neon. The cryogenic boiloff technique concentrated the fraction of the mass-2 isotope of hydrogen to a degree that made its spectroscopic identification unambiguous.
Girteka is a Lithuanian transport and logistics company based in the city of Vilnius, operating in Europe and Scandinavia. It was founded in 1996 by Mindaugas Raila who, at the age of 24, bought a single used truck complete with a trailer. Today, it is one of Europe's largest asset-based logistics companies. Girteka delivers more than 700,000 full truck loads (FTLs) every year, with more than 6,000 fully owned trucks and 7,000 trailers that operate across mainland Europe, the UK, and Scandinavia. Up to 95% of jobs are dispatched electronically, resulting in 97–99% DIFOT. Today, the company employs more than 13,000 people from more than 20 nationalities. Girteka has offices in Lithuania, Poland, Georgia, Denmark, Norway, Finland, Spain, Netherlands, Belgium, Ukraine, Belarus, Kazakhstan and Kyrgyzstan.
=== Infrared ear thermometers === Diatek Corporation and NASA developed an aural thermometer that measures the thermal radiation emitted by the eardrum, similar to the way the temperature of stars and planets are measured. This method avoids contact with mucous membranes and permits rapid temperature measurement of newborn or incapacitated patients. NASA supported the Diatek Corporation through the Technology Affiliates Program.
Each medal has a portrait of Alfred Nobel in left profile on the obverse. The medals for Chemistry, Literature, Physics, and Physiology or Medicine have identical obverses, showing the image of Nobel and the years of his birth and death. Nobel's portrait also appears on the obverse of the Peace Prize medal and the Economics Prize medal, but with a slightly different portrait. The names of the chemistry, medicine, literature and physics prize recipients are engraved on the reverse of the medal on a small plate. The names of the peace and economic prize recipients are engraved on the edges of their medals. The Chemistry, Literature, Physics, and Physiology or Medicine medals were designed by Erik Lindberg. The Peace prize medal was designed by Gustav Vigeland, and the Economics prize medal by Gunvor Svensson-Lundqvist. The inaugural Nobel laureates of 1901 received a 'temporary' medal that was struck in a lesser metal than gold. The first medals were eventually struck in September 1902. The delay was due to the designs needing to be approved by each respective awarding institution. The medals were designed by the sculptor Erik Lindberg. Between 1902 and 2010 the Nobel Prize medals were struck by the Myntverket, the Swedish royal mint, located in Eskilstuna. In 2011 the medals were made by Det Norske Myntverket in Kongsberg. The medals have been made by Svenska Medalj in Eskilstuna since 2012 with the exception of the peace prize medal which is made by the Det Norske Myntverket.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
Dry powder is held at minus twenty degrees Celsius or colder, away from light and moisture. Sealed vials under inert gas limit degradation during storage.